Previous 10 | Next 10 |
Personalis, Inc. (PSNL) Q3 2022 Earnings Conference Call November 2, 2022 17:00 ET Company Participants Caroline Corner - Investor Relations John West - President and Chief Executive Officer Aaron Tachibana - Chief Financial Officer Conference Call Particip...
Personalis press release ( NASDAQ: PSNL ): Q3 GAAP EPS of -$0.58 beats by $0.06 . Revenue of $14.9M (-33.2% Y/Y) beats by $1.26M . Gross margin was 16.7% in the three months ended September 30, 2022 Operating expenses were $29.7 million in the three months ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2022. Third Quarter and Recent Highlights Reported quarterly revenue of $14.9 million in the third quarter of 2...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the appointment of Christopher Hall as SVP and Head, Diagnostics Business. As part of the executive leadership team, Hall will drive the vision and strategy for commercializing Personalis’ ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2022 financial results on Wednesday, November 2, 2022. In conjunction with the release, Personalis will host a conference call and webcast that d...
Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...
Personalis, Inc. (Nasdaq: PSNL) has joined with Duke University and Olink Proteomics AB to form a research collaboration to study the effects of immunotherapy on advanced gastroesophageal cancer. Specifically, the collaboration will focus on identifying composite biomarkers—those...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Morgan Stanley 20 th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 1:30 p.m. Eastern Time in New York, NY. About Pers...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it has filed an amended complaint against Foresight Diagnostics. The amended complaint asserts a newly-issued patent in Personalis’ growing intellectual property portfolio relating to detec...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cathie Wood’s exchange-traded funds (ETFs) received a breath of fresh air this week. The ARK Innovation ETF (NYSEMKT: ARKK ) ended the period up over 12%. Wood did admit that she believes the U.S. is current...
News, Short Squeeze, Breakout and More Instantly...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tum...